Mini-Dose Glucagon as a Novel Approach to Prevent Exercise-Induced Hypoglycemia in Type 1 Diabetes.

Rickels MR, DuBose SN, Toschi E, Beck RW, Verdejo AS, Wolpert H, Cummins MJ, Newswanger B, Riddell MC

Diabetes care18 May 2018Cited by 58 (Europe PMC)

PMID29776987PMCIDPMC6463733DOI10.2337/dc18-0051PepBankPUB-29776987

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes, glucose increased slightly after mini-dose glucagon but decreased with no intervention during exercise and early recovery.
In plain wordsIn adults with type 1 diabetes, glucose rose slightly after mini-dose glucagon but fell with no intervention during exercise and early recovery.
Peptide
Glucagon
Outcome
IncreasePlasma glucose during exercise and early recovery
Study
n = 15
Comparator
no intervention
Outcome group
Glycemic control · Metabolic and weight
Studied dose
150 μg · subcutaneousAs given in this study (human).
Source sentences
Summary
During exercise and early recovery from exercise, plasma glucose increased slightly with MDG compared with a decrease with control and insulin reduction and a greater increase with glucose tablets (P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a four-session, randomized crossover trial involving 15 adults with type 1 diabetes treated with continuous subcutaneous insulin infusion who exercised fasting in the morning at ∼55% VO_2max for 45 min
Report a problemFND-2977698701
02HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes, glucose increased slightly after mini-dose glucagon but decreased with insulin reduction during exercise and early recovery.
In plain wordsIn adults with type 1 diabetes, glucose rose slightly after mini-dose glucagon but fell with insulin reduction during exercise and early recovery.
Peptide
Glucagon
Outcome
IncreasePlasma glucose during exercise and early recovery
Study
n = 15
Comparator
50% basal insulin reduction
Outcome group
Glycemic control · Metabolic and weight
Studied dose
150 μg · subcutaneousAs given in this study (human).
Source sentences
Summary
During exercise and early recovery from exercise, plasma glucose increased slightly with MDG compared with a decrease with control and insulin reduction and a greater increase with glucose tablets (P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a four-session, randomized crossover trial involving 15 adults with type 1 diabetes treated with continuous subcutaneous insulin infusion who exercised fasting in the morning at ∼55% VO_2max for 45 min
Report a problemFND-2977698702
03HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes, glucose increased less after mini-dose glucagon than glucose tablets during exercise and early recovery.
In plain wordsIn adults with type 1 diabetes, glucose rose less after mini-dose glucagon than glucose tablets during exercise and early recovery.
Peptide
Glucagon
Outcome
DecreasePlasma glucose during exercise and early recovery
Study
n = 15
Comparator
40-g oral glucose tablets
Outcome group
Glycemic control · Metabolic and weight
Studied dose
150 μg · subcutaneousAs given in this study (human).
Source sentences
Summary
During exercise and early recovery from exercise, plasma glucose increased slightly with MDG compared with a decrease with control and insulin reduction and a greater increase with glucose tablets (P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a four-session, randomized crossover trial involving 15 adults with type 1 diabetes treated with continuous subcutaneous insulin infusion who exercised fasting in the morning at ∼55% VO_2max for 45 min
Report a problemFND-2977698703
04HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes, insulin levels did not differ among mini-dose glucagon and the other sessions.
In plain wordsIn adults with type 1 diabetes, insulin levels did not differ between mini-dose glucagon and the other sessions.
Peptide
Glucagon
Outcome
No significant changeInsulin levels
Study
n = 15
Comparator
control, insulin reduction, and glucose tablet sessions
Outcome group
Glycemic control · Metabolic and weight
Studied dose
150 μg · subcutaneousAs given in this study (human).
Source sentences
Summary
Insulin levels were not different among sessions, whereas glucagon increased with MDG administration (P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a four-session, randomized crossover trial involving 15 adults with type 1 diabetes treated with continuous subcutaneous insulin infusion who exercised fasting in the morning at ∼55% VO_2max for 45 min
Report a problemFND-2977698704
05HumanRandomized controlled trialPharmacokinetics
In adults with type 1 diabetes, glucagon levels increased after mini-dose glucagon administration.
In plain wordsIn adults with type 1 diabetes, mini-dose glucagon increased glucagon levels.
Peptide
Glucagon
Outcome
IncreaseGlucagon levels
Study
n = 15
Outcome group
Pharmacokinetics · Endocrine and hormones
Studied dose
150 μg · subcutaneousAs given in this study (human).
Source sentences
Summary
Insulin levels were not different among sessions, whereas glucagon increased with MDG administration (P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a four-session, randomized crossover trial involving 15 adults with type 1 diabetes treated with continuous subcutaneous insulin infusion who exercised fasting in the morning at ∼55% VO_2max for 45 min
Report a problemFND-2977698705
06HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes, no subjects had hypoglycemia with mini-dose glucagon versus six with no intervention.
In plain wordsIn adults with type 1 diabetes, no subjects had hypoglycemia with mini-dose glucagon compared with six during no intervention.
Peptide
Glucagon
Outcome
DecreaseHypoglycemia
Study
n = 15
Comparator
no intervention
Outcome group
Glycemic control · Metabolic and weight
Studied dose
150 μg · subcutaneousAs given in this study (human).
Measurements
Subjects with hypoglycemia
6 subjects
control
Source sentences
Summary
Hypoglycemia (plasma glucose <70 mg/dL) was experienced by six subjects during control, five subjects during insulin reduction, and none with glucose tablets or MDG; five subjects experienced hyperglycemia (plasma glucose ≥250 mg/dL) with glucose tablets and one with MDG.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a four-session, randomized crossover trial involving 15 adults with type 1 diabetes treated with continuous subcutaneous insulin infusion who exercised fasting in the morning at ∼55% VO_2max for 45 min
Report a problemFND-2977698706
07HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes, no subjects had hypoglycemia with mini-dose glucagon versus five with insulin reduction.
In plain wordsIn adults with type 1 diabetes, no subjects had hypoglycemia with mini-dose glucagon compared with five during insulin reduction.
Peptide
Glucagon
Outcome
DecreaseHypoglycemia
Study
n = 15
Comparator
50% basal insulin reduction
Outcome group
Glycemic control · Metabolic and weight
Studied dose
150 μg · subcutaneousAs given in this study (human).
Measurements
Subjects with hypoglycemia
5 subjects
insulin reduction
Source sentences
Summary
Hypoglycemia (plasma glucose <70 mg/dL) was experienced by six subjects during control, five subjects during insulin reduction, and none with glucose tablets or MDG; five subjects experienced hyperglycemia (plasma glucose ≥250 mg/dL) with glucose tablets and one with MDG.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a four-session, randomized crossover trial involving 15 adults with type 1 diabetes treated with continuous subcutaneous insulin infusion who exercised fasting in the morning at ∼55% VO_2max for 45 min
Report a problemFND-2977698707
08HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes, no subjects had hypoglycemia with mini-dose glucagon or with glucose tablets.
In plain wordsIn adults with type 1 diabetes, no one had hypoglycemia with mini-dose glucagon or with glucose tablets.
Peptide
Glucagon
Outcome
Not applicableHypoglycemia
Study
n = 15
Comparator
40-g oral glucose tablets
Outcome group
Glycemic control · Metabolic and weight
Studied dose
150 μg · subcutaneousAs given in this study (human).
Source sentences
Summary
Hypoglycemia (plasma glucose <70 mg/dL) was experienced by six subjects during control, five subjects during insulin reduction, and none with glucose tablets or MDG; five subjects experienced hyperglycemia (plasma glucose ≥250 mg/dL) with glucose tablets and one with MDG.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a four-session, randomized crossover trial involving 15 adults with type 1 diabetes treated with continuous subcutaneous insulin infusion who exercised fasting in the morning at ∼55% VO_2max for 45 min
Report a problemFND-2977698708
09HumanRandomized controlled trialSafety outcome
In adults with type 1 diabetes, one subject had hyperglycemia with mini-dose glucagon versus five with glucose tablets.
In plain wordsIn adults with type 1 diabetes, one subject had hyperglycemia with mini-dose glucagon compared with five with glucose tablets.
Peptide
Glucagon
Outcome
DecreaseHyperglycemia
Study
n = 15
Comparator
40-g oral glucose tablets
Outcome group
Glycemic control · Metabolic and weight
Studied dose
150 μg · subcutaneousAs given in this study (human).
Measurements
Subjects with hyperglycemia
5 subjects
glucose tablets
Subjects with hyperglycemia
1 subjects
mini-dose glucagon
Source sentences
Summary
Hypoglycemia (plasma glucose <70 mg/dL) was experienced by six subjects during control, five subjects during insulin reduction, and none with glucose tablets or MDG; five subjects experienced hyperglycemia (plasma glucose ≥250 mg/dL) with glucose tablets and one with MDG.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a four-session, randomized crossover trial involving 15 adults with type 1 diabetes treated with continuous subcutaneous insulin infusion who exercised fasting in the morning at ∼55% VO_2max for 45 min
Report a problemFND-2977698709

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT02660242

The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes

Jaeb Center for Health Researchn = 16Jan 2016 to 15 Feb 2017

Diabetes Mellitus, Type 1

Trial page ClinicalTrials.govUpdated 3 Mar 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.